Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Recurrence × 90Y-octreotide, DOTA-Tyr(3)- × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 2 Neuroblastoma 2 Meningioma 2 Medulloblastoma 2 Small Cell Lung Carcinoma 1 Recurrence 1 Lymphoma, Mantle-Cell 1 Lung Neoplasms 1 Breast Neoplasms, Male 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 55 Dexamethasone 44 Rituximab 36 Paclitaxel 27 Lenalidomide 26 Peripheral Blood Stem Cell Transplantation 25 Etoposide 24 fludarabine phosphate 23 Gemcitabine 23 Busulfan 23 Cytarabine 22 Bortezomib 22 Bevacizumab 21 Radiotherapy 20 pembrolizumab 19 Melphalan 18 Cisplatin 18 Carboplatin 18 Mycophenolic Acid 17 pomalidomide 16 fludarabine 16 Oxaliplatin 16 Filgrastim 16 Cyclosporine 15 Antilymphocyte Serum 15 Methotrexate 14 Whole-Body Irradiation 13 Bendamustine Hydrochloride 13 Tacrolimus 12 Methylprednisolone 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02488512 2018-03-19

itTRIOlym

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated

Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡